30 Nov 2017 Jahr - FDA approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine- containing product. It is indicated for patients that have been on a stable dose of buprenorphine treatment for a minimum of seven days.
Zugefügt zum Band der Zeit:
Datum:
30 Nov 2017 Jahr
Jetzt
~ 7 years and 10 months ago